Characterization and Optimization of a Novel Protein–Protein Interaction Biosensor High-Content Screening Assay to Identify Disruptors of the Interactions Between p53 and hDM2

Autor: Drew D. Dudgeon, Paul A. Johnston, Patricia A. Johnston, John S. Lazo, Christopher J. Strock, Kenneth A. Giuliano, Sunita Shinde, Tong Ying Shun, D. Lansing Taylor

Publikováno v: ASSAY and Drug Development Technologies. 8:437-458

We present here the characterization and optimization of a novel imaging-based positional biosensor high-content screening (HCS) assay to identify disruptors of p53-hDM2 protein–protein interactions (PPIs). The chimeric proteins of the biosensor in

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0c150a85a03f6bb6cb3d1461899f25e4
https://doi.org/10.1089/adt.2010.0281

Multiple Signaling Pathways Regulate Yeast Cell Death during the Response to Mating Pheromones

Autor: Saurabh Paliwal, Nannan Zhang, Drew D. Dudgeon, Andre Levchenko, Eric Grote, Kyle W. Cunningham

Publikováno v: Molecular Biology of the Cell. 17:3409-3422

Mating pheromones promote cellular differentiation and fusion of yeast cells with those of the opposite mating type. In the absence of a suitable partner, high concentrations of mating pheromones induced rapid cell death in ∼25% of the population o

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c7978b820ee84dd2fa46b44fb098b225
https://doi.org/10.1091/mbc.e06-03-0177

Implementation of a 220,000-compound HCS campaign to identify disruptors of the interaction between p53 and hDM2 and characterization of the confirmed hits

Autor: Tong Ying Shun, John S. Lazo, Kenneth A. Giuliano, Paul A. Johnston, Christopher J. Strock, D. Lansing Taylor, Drew D. Dudgeon, Patricia A. Johnston, Sunita Shinde, Yun Hua

Publikováno v: Journal of biomolecular screening. 15(7)

In recent years, advances in structure-based drug design and the development of an impressive variety of high-throughput screening (HTS) assay formats have yielded an expanding list of protein-protein interaction inhibitors. Despite these advances, p

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::982a5c1ccf133fedfeedb846017f5de2
https://pubmed.ncbi.nlm.nih.gov/20639499

A PD-1-targeted, receptor-masked IL-2 immunocytokine that engages IL-2Rα strengthens T cell-mediated anti-tumor therapies.

Autor: Wu J; Regeneron Pharmaceuticals, Inc., Tarrytown, NY 10591, USA. Electronic address: jiaxi.wu@regeneron.com., Bloch N; Regeneron Pharmaceuticals, Inc., Tarrytown, NY 10591, USA., Chang AY; Regeneron Pharmaceuticals, Inc., Tarrytown, NY 10591, USA., Bhavsar R; Regeneron Pharmaceuticals, Inc., Tarrytown, NY 10591, USA., Wang Q; Regeneron Pharmaceuticals, Inc., Tarrytown, NY 10591, USA., Crawford A; Regeneron Pharmaceuticals, Inc., Tarrytown, NY 10591, USA., DiLillo DJ; Regeneron Pharmaceuticals, Inc., Tarrytown, NY 10591, USA., Vazzana K; Regeneron Pharmaceuticals, Inc., Tarrytown, NY 10591, USA., Mohrs K; Regeneron Pharmaceuticals, Inc., Tarrytown, NY 10591, USA., Dudgeon D; Regeneron Pharmaceuticals, Inc., Tarrytown, NY 10591, USA., Patel S; Regeneron Pharmaceuticals, Inc., Tarrytown, NY 10591, USA., Ahmed H; Regeneron Pharmaceuticals, Inc., Tarrytown, NY 10591, USA., Garg V; Regeneron Pharmaceuticals, Inc., Tarrytown, NY 10591, USA., Amatulli M; Regeneron Pharmaceuticals, Inc., Tarrytown, NY 10591, USA., Antao OQ; Regeneron Pharmaceuticals, Inc., Tarrytown, NY 10591, USA., Yan Y; Regeneron Pharmaceuticals, Inc., Tarrytown, NY 10591, USA., Wang S; Regeneron Pharmaceuticals, Inc., Tarrytown, NY 10591, USA., Ramos W; Regeneron Pharmaceuticals, Inc., Tarrytown, NY 10591, USA., Krueger P; Regeneron Pharmaceuticals, Inc., Tarrytown, NY 10591, USA., Adler C; Regeneron Pharmaceuticals, Inc., Tarrytown, NY 10591, USA., Ni M; Regeneron Pharmaceuticals, Inc., Tarrytown, NY 10591, USA., Wei Y; Regeneron Pharmaceuticals, Inc., Tarrytown, NY 10591, USA., Guo C; Regeneron Pharmaceuticals, Inc., Tarrytown, NY 10591, USA., Macdonald L; Regeneron Pharmaceuticals, Inc., Tarrytown, NY 10591, USA., Huang T; Regeneron Pharmaceuticals, Inc., Tarrytown, NY 10591, USA., Ullman E; Regeneron Pharmaceuticals, Inc., Tarrytown, NY 10591, USA., Hermann A; Regeneron Pharmaceuticals, Inc., Tarrytown, NY 10591, USA., Yancopoulos GD; Regeneron Pharmaceuticals, Inc., Tarrytown, NY 10591, USA., Murphy AJ; Regeneron Pharmaceuticals, Inc., Tarrytown, NY 10591, USA., Davis S; Regeneron Pharmaceuticals, Inc., Tarrytown, NY 10591, USA., Olson WC; Regeneron Pharmaceuticals, Inc., Tarrytown, NY 10591, USA., Lin JC; Regeneron Pharmaceuticals, Inc., Tarrytown, NY 10591, USA., Smith E; Regeneron Pharmaceuticals, Inc., Tarrytown, NY 10591, USA., Zhang T; Regeneron Pharmaceuticals, Inc., Tarrytown, NY 10591, USA.

Publikováno v: Cell reports. Medicine [Cell Rep Med] 2024 Oct 15; Vol. 5 (10), pp. 101747. Date of Electronic Publication: 2024 Sep 25.

Structural analysis of cancer-relevant TCR-CD3 and peptide-MHC complexes by cryoEM.

Autor: Saotome K; Regeneron Pharmaceuticals, Inc., Tarrytown, NY, 10591, USA. kei.saotome@regeneron.com., Dudgeon D; Regeneron Pharmaceuticals, Inc., Tarrytown, NY, 10591, USA., Colotti K; Regeneron Pharmaceuticals, Inc., Tarrytown, NY, 10591, USA., Moore MJ; Regeneron Pharmaceuticals, Inc., Tarrytown, NY, 10591, USA., Jones J; Regeneron Pharmaceuticals, Inc., Tarrytown, NY, 10591, USA., Zhou Y; Regeneron Pharmaceuticals, Inc., Tarrytown, NY, 10591, USA., Rafique A; Regeneron Pharmaceuticals, Inc., Tarrytown, NY, 10591, USA., Yancopoulos GD; Regeneron Pharmaceuticals, Inc., Tarrytown, NY, 10591, USA., Murphy AJ; Regeneron Pharmaceuticals, Inc., Tarrytown, NY, 10591, USA., Lin JC; Regeneron Pharmaceuticals, Inc., Tarrytown, NY, 10591, USA., Olson WC; Regeneron Pharmaceuticals, Inc., Tarrytown, NY, 10591, USA., Franklin MC; Regeneron Pharmaceuticals, Inc., Tarrytown, NY, 10591, USA. matthew.franklin@regeneron.com.

Publikováno v: Nature communications [Nat Commun] 2023 Apr 26; Vol. 14 (1), pp. 2401. Date of Electronic Publication: 2023 Apr 26.